
Ivary
Enables women freedom in family and life planning with the Ovarian Reserve Test.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor investor | €0.0 | round | |
N/A | Acquisition | ||
Total Funding | 000k |
Related Content
Ivary, founded in Vienna, Austria, in 2014 by Silvia Hecher, operated in the burgeoning femtech market with a direct-to-consumer model. The company provided an at-home diagnostic kit designed to assess a woman's ovarian reserve, offering a quantitative measure of her remaining egg cells to inform life and family planning decisions.
The business operated through an online platform where consumers could order the testing kit. The process involved the customer collecting a blood sample at home, mailing it to a partner laboratory for analysis, and subsequently receiving a detailed report of the results via email. This approach offered a private and accessible way for women to gain insight into their reproductive health.
From a financial perspective, Ivary secured a significant milestone with a seed funding round on February 28, 2017, raising $1.27 million. This investment was led by Speedinvest, with participation from Pioneers and angel investor Hansi Hansmann, indicating investor confidence in its niche market position. The company's journey concluded in May 2018 when it was acquired by Bloom Diagnostics, and it is no longer active as a standalone entity. The founder, Silvia Hecher, has since gone on to establish another company in the health sector, LEVY Health.
Keywords: femtech, ovarian reserve test, at-home diagnostics, reproductive health, fertility testing, health diagnostics, biotechnology, direct-to-consumer health, Vienna startup, Silvia Hecher, Speedinvest, women's health, blood sample test, family planning, egg cell count, health technology, diagnostic kits, medical diagnostics